DZ
DefZone.Net

Kien thuc cong nghe & giai tri

Wiki Article

ZYN-001

Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net

Xem trên WikipediaBài ngẫu nhiên khác

ZYN-001
Clinical data
Other namesZYN001; Δ9-Tetrahydrocannabinol D-glyceric acid ester; Δ9-THC D-glyceric acid ester; Tetrahydrocannabinol prodrug; Tetrahydrocannabinol prodrug transdermal patch; THC prodrug; THC prodrug transdermal patch
Routes of
administration		Transdermal (patch)[1][2]
Drug classCannabinoid; Cannabinoid CB1 and CB2 receptor agonist
Identifiers
  • [(6aR,10aR)-6,6,9-trimethyl-3-pentyl-6a,7,8,10a-tetrahydrobenzo[c]chromen-1-yl] 2,3-dihydroxypropanoate
CAS Number
PubChem CID
Chemical and physical data
FormulaC24H34O5
Molar mass402.531 g·mol−1
3D model (JSmol)
  • CCCCCC1=CC2=C([C@@H]3C=C(CC[C@H]3C(O2)(C)C)C)C(=C1)OC(=O)C(CO)O
  • InChI=1S/C24H34O5/c1-5-6-7-8-16-12-20(28-23(27)19(26)14-25)22-17-11-15(2)9-10-18(17)24(3,4)29-21(22)13-16/h11-13,17-19,25-26H,5-10,14H2,1-4H3/t17-,18-,19?/m1/s1
  • Key:WUPURSKTAUGQRZ-PWCSWUJKSA-N

ZYN-001, also known as Δ9-tetrahydrocannabinol D-glyceric acid ester, is a cannabinoid which was under development for the treatment of cancer pain, neuropathic pain, fibromyalgia, and Tourette's syndrome but was never marketed.[1][3][2][4][5] It was formulated as a transdermal patch.[1][2][4] The drug is a synthetic prodrug of Δ9-tetrahydrocannabinol (Δ9-THC) and acts as a cannabinoid CB1 and CB2 receptor agonist.[1][2][4][5] ZYN-001 was under development by Zynerba Pharmaceuticals.[1][3][2][4] It reached phase 1 clinical trials prior to the discontinuation of its development in 2018.[1][3][2][4] The drug was discontinued after it failed to attain target THC blood levels of 5 to 15 ng/mL in a phase 1 trial.[4]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "ZYN 001". AdisInsight. 13 October 2023. Retrieved 18 January 2026.
  2. ^ a b c d e f Philippidis A (5 July 2018). "Zynerba Scraps Development of THC Prodrug ZYN001 after Failed Trial". GEN - Genetic Engineering and Biotechnology News. Retrieved 18 January 2026.
  3. ^ a b c "Delving into the Latest Updates on ZYN-001 with Synapse". Synapse. 27 December 2025. Retrieved 18 January 2026.
  4. ^ a b c d e f Stella B, Baratta F, Della Pepa C, Arpicco S, Gastaldi D, Dosio F (September 2021). "Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain". Drugs. 81 (13): 1513–1557. doi:10.1007/s40265-021-01579-x. PMC 8417625. PMID 34480749. The case of Zynerba Pharmaceuticals Inc. (USA), who developed a synthetic d-glyceric acid ester pro-drug of THC administered as a transdermal patch (ZYN001 at 36 mg dose), is indicative of the complexities inherent in properly delivering cannabinoids through the skin [219]. Zynerba conducted Phase I development in the treatment of fibromyalgia and neuropathic pain in Australia. However, development was subsequently discontinued (year 2018) because the study indicated that target blood levels of 5–15 ng/mL THC were not achieved.
  5. ^ a b Ujváry I, Evans-Brown M, Gallegos A, Planchuelo G, de Morais J, Christie R, et al. (2023). Technical Report: Hexahydrocannabinol (HHC) and related substances (PDF) (Report). European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information.

Stub icon

This analgesic-related article is a stub. You can help Wikipedia by adding missing information.